Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.

@article{Scotece2013OleocanthalIP,
  title={Oleocanthal inhibits proliferation and MIP-1$\alpha$ expression in human multiple myeloma cells.},
  author={Morena Scotece and Rodolfo G{\'o}mez and Javier Conde and Ver{\'o}nica L{\'o}pez and Juan J G{\'o}mez-Reino and Francisca Lago and A. B. Iii Smith and Oreste Gualillo},
  journal={Current medicinal chemistry},
  year={2013},
  volume={20 19},
  pages={
          2467-75
        }
}
Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1 α) is crucially involved in the development of osteolytic bone lesions in MM… 

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

Oleacein is endowed with HDAC inhibitory properties, which associate with significant anti-MM activity both as single agent or in combination with carfilzomib, and may pave the way to novel potential anti- MM epi-therapeutic approaches based on natural agents.

(-)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway.

The effects of (-)-oleocanthal (OC) on the three processes in melanoma are explored, and underlying mechanisms are investigated to support further investigation of OC as a potential anti-melanoma drug.

Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation.

Oleocanthal treatment was found to exert a potent anticancer activity against HCC and CRC cells, providing preclinical support of the chemotherapeutic potential of EVOO against cancer.

Anticancer molecular mechanisms of oleocanthal

This review summarizes the current advancers concerning the anticancer activity of OLC, with particular emphasis on the molecular signaling pathways modulated by this compound in different tumor cell types.

Cytotoxic Activity of Oleocanthal Isolated from Virgin Olive Oil on Human Melanoma Cells

Cell viability experiments carried out by WST-1 assay demonstrated that oleocanthal had a remarkable and selective activity for human melanoma cells versus normal dermal fibroblasts with IC50s in the low micromolar range of concentrations, which may suggest that extra virgin olive oil phenolic extract enriched in oleOCanthal deserves further investigation in skin cancer.

(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer

Daily oral treatment with 10 mg/kg OC for 8 weeks significantly suppressed the LC A549-Luc progression and prevented metastasis to brain and other organs in a nude mouse tail vein injection model, showing the novel ability of OC to suppress LC progression and metastasis through dual targeting of c-MET and COX-2.

Olive Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth in Breast Cancer Models

The findings of this study suggest that (-)-oleocanthal is a promising dietary supplement lead with potential for therapeutic use to control malignancies with aberrant c-Met activity.

Oleocanthal Inhibits Catabolic and Inflammatory Mediators in LPS-Activated Human Primary Osteoarthritis (OA) Chondrocytes Through MAPKs/NF-κB Pathways

Oleocanthal is able to block LPS-mediated inflammatory response and MMP-13 and ADAMTS-5 induction in human primary OA chondrocytes via MAPKs/NF-kB pathways, suggesting that OC may be a promising agent for the treatment of inflammation in cartilage and a potential molecule to prevent disease progression by inhibiting metalloproteases and aggrecanases.

The Biological Activities of Oleocanthal from a Molecular Perspective

Oleocanthal may act together with other bioactive compounds in olive oil to achieve its therapeutic potential and the use of oleOCanthal alone as a single therapeutic measure awaits validation from future studies.
...

References

SHOWING 1-10 OF 32 REFERENCES

Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.

An overview of the literature focusing on the mechanisms implicated in the "angiogenic switch", which corresponds to the transition from the avascular to the vascular phase of the disease is presented, and evidence on the anti-angIogenic effects of PI and IMiDs are reviewed, which substantially contribute to their anti-MM activity.

A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function

Results show that CCL3, in addition to its known catabolic activity, reduces bone formation by inhibiting OB function, and therefore contributes to OB/OC uncoupling in MM.

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

The potent in vitro and in vivo antimyeloma activity of Zalypsis uncovers the high sensitivity of tumor plasma cells to DSBs and strongly supports the use of this compound in MM patients.

Macrophage inflammatory protein-1α (MIP-1α) enhances a receptor activator of nuclear factor κB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways

It is suggested that activation of the MEK/ERK and the PI3K/Akt pathways and inhibition of p38MAPK pathway were involved in RANKL expression induced by MIP-1α in bone-marrow stromal cells and osteoblasts and that this finding may be useful in the development of an osteoclastic inhibitor that targets intracellular signaling factors.

Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells

Oleuropein or hydroxytyrosol, major phenolic compound of olive oil, was studied for its effects on growth in MCF-7 human breast cancer cells using assays for proliferation, cell viability, inhibited cell proliferation, and induced cell apoptosis.

Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line.

This class of molecules shows potential as a therapeutic weapon for the treatment of inflammatory degenerative joint diseases because of its inhibitory effect on NOS2, which is devoid of cytotoxicity even at higher concentrations.

Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.

It is suggested that activation of the MEK/ERK and the PI3K/Akt pathways and inhibition of p38MAPK pathway were involved in RANKL expression induced by MIP-1alpha in bone-marrow stromal cells and osteoblasts, and this finding may be useful in the development of an osteoclastic inhibitor that targets intracellular signaling factors.

Impact of bortezomib on bone health in myeloma: a review of current evidence.